Physician profile
Vineeth N Kumar
NPI 1689108680
$12,857.89
in general payments reported to CMS, 2019-2025
64 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $414 · 2021: $2,412 · 2022: $3,667 · 2023: $2,026 · 2024: $2,216 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,364.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $1,747.49 | 2022 | |
| Abbvie INC. | $1,358.95 | 2021-2025 | |
| Amgen INC. | $821.24 | 2020-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $717.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $609.30 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $601.61 | 2023-2025 | Gemtesa |
| Pfizer INC. | $577.36 | 2021-2025 | |
| Abbott Laboratories | $529.53 | 2021-2024 | Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $517.00 | 2021-2025 | |
| Corium, LLC | $495.79 | 2023-2025 | Azstarys |
| Esperion Therapeutics, INC. | $489.14 | 2020-2023 | Nexletol |
| Glaxosmithkline, LLC. | $465.16 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $353.25 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Cardiovascular Systems INC. | $340.83 | 2021-2023 | Diamondback Peripheral |
| Astellas Pharma US INC | $198.26 | 2021-2025 | Veozah |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineeth Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.